
Valeant Pharmaceuticals Completes \$365 Million Rule 144A Offering

Date: 06/09/09

Cahill represented UBS Securities LLC and the other initial purchasers in the \$365,000,000 Rule 144A Offering by Valeant Pharmaceuticals International of its 8.375% Senior Notes due 2016. The proceeds will be used for general corporate purposes, which may include funding securities repurchases.

Attorney

- Noah B. Newitz